Boehringer In­gel­heim is think­ing in block­buster terms as it throws its hat in­to the ever-widen­ing CD47 ring

Boehringer In­gel­heim is jump­ing on­to the CD47 “don’t-eat-me” path­way.

The Ger­man com­pa­ny is pay­ing $37 mil­lion in cash and near-term mile­stones to grab rights to one of the prime tar­gets in the in­ter­play be­tween CD47 and SIRP-al­pha. By tar­get­ing SIRP-al­pha and pre­vent­ing CD47 from bind­ing to it, in­ves­ti­ga­tors at Boehringer be­lieve that they can defuse a key im­muno­sup­pres­sant and al­low macrophages to go on a can­cer cell ram­page.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER